AMYLIN PHARMACEUTICALS IPO RAISES $56 MIL. on Jan. 17 with 4 mil. shares going for $14 per share. The offering increased substantially in size and price from the estimates in a Nov. 27 prospectus filed with the Securities & Exchange Commission. The prospectus estimated a price of $10 per share for 3 mil. shares. The offering, underwritten by Morgan Stanley and Alex. Brown, testifies to the continued interest in new biotech offerings despite a recent softening in the market for biotech shares. Proceeds will support San Diego-based Amylin's research and development efforts for diabetes and obesity based on the pancreatic hormone amylin, as well as other general corporate purposes. The company is ready to carry its R&D into human clinicals: the firm filed an IND on Dec. 10. Initial clinical trials will focus on the clinical pharmacology of amylin in replacement therapy applications. Future applications may include amylin blockade therapy for both diabetes and obesity, as well as possible amylin agonist use for treatment of osteoporosis, the company said. Amylin announced Jan. 6 that former Burroughs Wellcome researcher Robert Butz, PhD, has joined the company as vice president of development. Butz most recently served as VP-clinical operations for the international contract research organization Quintiles. At Amylin, Butz will be responsible for preclinical development, clinical R&D, clinical data management and project management. Amylin is working with Glaxo in the blockade therapy area under an agreement signed in October ("The Pink Sheet" Nov. 4, T&G-1). As part of the collaboration, each firm will assign 20 to 35 scientists to a joint effort to "develop amylin blockers for the treatment of adult onset diabetes," the prospectus says. In exchange for an upfront $2 mil. research fee, Glaxo has exclusive rights to commercialize any product candidates, while Amylin retains the right to copromote any marketable products on a product-by-product, market-by-market basis, "subject to reimbursing Glaxo for certain development costs." Glaxo has no equity stake in Amylin. Amylin retains all commercial rights to its amylin replacement therapy for diabetes indications and at present plans to undertake all clinicals, manufacturing and marketing, the prospectus notes. "The company plans to file additional INDs on amylin-based compounds for treating severe hypoglycemia in insulin-dependent diabetics, for reducing the risk of insulin-induced hypoglycemia, and for treating an underlying cause of adult onset diabetes," the prospectus adds.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
EU authorities must “take advantage” of the upcoming Biotech Act to reassess the bloc’s policies and “offset existing challenges” for small and midsized enterprises, trade association EUCOPE has said.
The whole contract research organization industry is being impacted by the current volatility in the pharmaceutical industry.
The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get your submissions in by this date. Sponsorship opportunities and tables for the event are also available.
